anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tablet supplement comprising only natural materials using Brassica oleracea var. acephala as a vehicle, a hydrogenated rape seed oil as a lubricant, and maltose for enhancing flowability.  &lt;P&gt;SOLUTION: This tablet supplement is characterized in that it is prepared by adding and mixing powdery Brassica oleracea var. acephala prepared by drying the Brassica oleracea var. acephala and then crushing the dried product to a powdery supplement raw material.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cornoid lemella-removing sheet even easier to visually recognize cornoid lemella removed from the skin with no need of bringing a color pigment in a wet adhesive to high concentrations.  &lt;P&gt;SOLUTION: The cornoid lemella-removing sheet is obtained by holding, in a colored moisture-permeable holding material, the wet adhesive comprising (A) a water-soluble polymer that exhibits adhesivity in the presence of an aqueous medium, (B) a liquid plasticizer, (C) a filler and (D) the color pigment. In this cornoid lemella-removing sheet, it is preferable that the color pigment be e.g. black iron oxide, red iron oxide, carbon black, ultramarine, iron blue pigment, and the moisture-permeable holding material be a nonwoven fabric. Besides, it is preferable that the L-values and the b-values of the moisture-permeable holding material and the wet adhesive layer in the L*a*b* color specification system be 50 or less and 10 or less, respectively.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To obtain a shampoo compsn. having more satisfactory conditioning characteristics. CONSTITUTION: A quat. imidazolinium compd. is added to a shampoo compsn. consisting of an anionic surfactant, a nonionic surfactant or a mixture of them, a suspending aid, nonvolatile silicone and water to obtain the objective shampoo compsn. having improved silicone depositing characteristics and conditioning characteristics. It is preferable that alkylene glycol monostearate or distearate is further added. About &gt;0.1 g of this shampoo compsn. is applied to wetted hair and rinsed off.
Methods for providing online health monitoring (16) and accumulating data from patients worldwide and accompanying apparatus for using the same, are disclosed. Such monitoring is particularly useful for both diagnosing and prescribing preventive medical treatment, and is particularly suited for the field of cardiovascular health care. Preferred methods and devices include using a sensitive acoustic device such as an electret, to analyze a patient&#39;s cardiovascular functions from a location such as a public computer kiosk, a doctor&#39;s office or a patient&#39;s home computer. The data may be downloaded from an acoustic device to a central database located, for example on the Internet. The data may be retrieved by the patient, or upon instructions from the patient, may be transferred to or accessed by doctors for purposes of diagnosis, monitoring and treatment. Data may include patient demographics. This data is accessible by researchers who will have medical statistics on a wide variety of patients from various age groups and medical histories.
Vaccine comprising a virus having the designation ATCC VR2509 is claimed. Also claimed are: (1) an isolated and purified North American porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) strain where the strain has the designation ATCC VR2509, and (2) an isolated and purified PRRSV strain, wherein the strain gives plaques having an average dia. of  2 mm when the plaques are obtd. by a method comprising: (a) inoculating an aliquot of cells with the strain, where the cells have the designation ATCC VR2509, where the aliquot is obtd. from a confluent monolayer of the cells maintained in Eagle&#39;s min. essential medium (MEM) supplemented with 3% fetal calf serum and 0.15% sodium carbonate, where the aliquot includes 1-2\*105 cells/ml of MEM, (b) incubating the aliquot at 37  deg C for 60 mins, (c) removing the inoculum from the aliquot, (d) washing the aliquot with MEM, (e) resuspending the aliquot in 5 ml of 2X MEM and 1.6% boiled Noble agar supplemented with 250 ~mg of diethylaminoethyl (DEAE)- dextran, (f) plating the aliquot and (g) further incubating the aliquot at 37  deg C for 5 days in CO2 incubator to give the plaques.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sheet-like cosmetic material not only having appearance providing an impression of good wipeability, but also having good wipeability in use, good touch feeling and good sense of use hardly causing twisting.  &lt;P&gt;SOLUTION: In the sheet-like cosmetic material, a web layer A comprising a viscose rayon using cotton linters as a starting material as a constituent fiber, and a web B including a fusing fiber in a constituent fiber are laminated, and the constituent fibers of the web A and the web B are mutually interlaced to provide a spunlace nonwoven fabric. The spunlace nonwoven fabric and a heat-fusible sheet including the fusing fiber are laminated in order of web A/web B/heat-fusible sheet/web B/web A. The sheet material is constituted by integrating the laminate by forming a shape in which an uneven pattern is formed by hot embossing at least on one surface of the laminate. Also provided is a sheet material which is prepared by the impregnation of a liquid material to the above sheet like material.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
An approach is disclosed for achieving improved egg quality and simplified management in patient undergoing controlled ovarian stimulation. Information, including endogenous FSH level, is received about the patient. An optimal duration for the controlled ovarian stimulation is estimated. A target level of FSH is estimated to achieve the optimal duration. Pharmacological formulations are administered to change FSH to achieve the target level of FSH. Resulting FSH is compared to target FSH level. The amount of pharmacological formulation is adjusted when the target FSH level is not achieved; and oocyte&#39;s final maturation is triggered after achieving the optimal duration.
NEW MATERIAL:A styrene derivative expressed by formula I (X is H or halogen; X&#39; and X are the same or different halogen; R is H or lower alkyl; Y is carboxyl, carboxyl having H substituted by mono - trivalent metallic atom or carboxyl having organic amine added thereto, hydroxymethyl, carbamoyl or carbohydroxamly). EXAMPLE:2-[4-(2,2-Dichlorovinyl)phenyl]propionic acid. USE:A medicine having anti-inflammatory, antipyretic and analgesic action. PREPARATION:A compound expressed by formula II (Z is carboxyl or nitrile) is converted into a diazonium salt, which is then reacted with a 1,1-dihalogenoethylene to give a compound expressed by formula III. The resultant compound expressed by formula III is treated with an alkali to afford the aimed compound expressed by formula I (Y is carboxyl group). In case the group Z is nitrile, the group Z is converted into the carboxyl group by hydrolysis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin care preparation for sites around the eyes, consisting of a composition containing coix seed and associated with new applications, and capable of ameliorating dark areas, small wrinkles and swelling.  &lt;P&gt;SOLUTION: The skin care preparation comprises coix seed and/or its extract, a cell proliferation promoter and a blood circulation promoter. As the cell proliferation promoter, a plant such as aloe, Taraxacum officinale, Cnidium officinale, Mulberry bark, carrot or hop, or its extract is used. As the blood circulation promoter, vitamin E and/or its derivative, a plant such as almond, peanut, perilla or pumpkin, or its extract is used. This skin care preparation is useful for ameliorating dark areas, small wrinkles and swelling around the eyes.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
A web-based platform for guiding a user&#39;s encounter with a patient and for generating a medical record of the encounter. The web-based platform comprises a processor in communication with an output display device and an input user interface, a knowledge base. The processor outputs information to the output display device, accesses the knowledge base, and receives information from the input user interface. The output display device requests patient information in response to presented successive prompts for patient medical information. The prompts are responsive to the knowledge base and to prior responses to prior prompts as entered through the input user interface. The output display device presents a patient medical condition report based on responses to requests and prompts. ICD codes are included within the knowledge base and included within the patient medical condition report. The codes are determined, as applicable, as each prompt and response is entered.
ABSTRACT OF THE DISCLOSURE           Method and apparatus for use in the diag-nostic analysis of a liquid specimen through binding assays.  The apparatus includes a rigid body having an elongated, shallow well formed in it, with a plurality of elongated strips, preferably in the form of cotton threads, stretched across the well in spaced relationship and generally perpendicular to the well&#39;s longitudinal axis.  Each thread is coated with a separate binding conjugate such as an antigen or allergen.  A cover plate that includes a thin plastic layer and an overlaying thin metallic layer covers the well to form an enclosed chamber having a specific volume.   The metallic layer includes a separate elongated aperture in alignment with each coated thread.  A liquid specimen is introduced into the chamber through one of two ports, for incubation with the coated threads, after which the specimen is removed and the reaction that occurred on each thread is deter-mined.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition that even an elderly person having difficulty in swallowing easily takes and masks bitterness of amlodipine besilate.  &lt;P&gt;SOLUTION: The pharmaceutical composition is obtained by coating amlodipine besilate alone or a mixture of amlodipine besilate and an excipient with a coating agent containing one or more selected from the group consisting of a water-insoluble polymer, an enteric polymer and a gastrosoluble polymer. The amount of the coating agent is 0.5-1.5 pts.wt. based on 1 pt.wt. of amlodipine besilate.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention discloses tea-flavored white spirit, which is prepared from the following raw materials (by weight): 500-510 parts of rice, 18-19 parts of tea, 10-11 parts of wheatberry, 2-3 parts of cornua cervi pantotrichum, 1-2 parts of rosa rugosa, 3-4 parts of rhodiola, 2-3 parts of ganoderma lucidum, 5-6 parts of baking soda, 0.25-0.3 part of saccharifying enzyme, 0.1-0.2 part of amylase, a proper amount of lactic acid, 5-6 parts of distiller&#39;s yeast, 0.8-0.9 part of chitosan, and 1-1.2 parts of carrageenan. After roasted and puffed, the raw material rice has a porous and loose structure, which is beneficial to saccharifying enzyme catalyzed hydrolysis. The introduced superheated steam has large heat transfer coefficient, thus accelerating heating rate of rice. After baking soda is dissolved in water, hydroxide ions are ionized out of the solution. Therefore, association among water molecules is weakened, degree of freedom of water molecules is increased, and water molecules are easy to enter rice starch molecules to swell rice and enhance degree of gelatinization. With the addition of chitosan and carrageenan, gastric acid which is produced under stimulation of alcohol can be neutralized, thus reducing stimulus. In addition, the product is anti-aging.
FIELD: medicine, biotechnology, microbiology. SUBSTANCE: method involves the submerged periodic culturing the selected strain of mycelial fungi with stable trait of intense germination of conidia and spores in flasks at shaking 100 rev/min using shuttle-apparatus at 27 C and by the directed biosynthesis using supplements of yeast extract in the concentration 0.5% taken in the amount 1 ml to the basic Saburo&#39;s medium. Control is carried out by recording maximal yield of allergen- -active components, accumulation of biomass, protein nitrogen and cytomorphological changes of mycelium in dynamics of culturing fungi. Filtrate of cultural fluid prepared by the developed method for growing fungal allergens shows high specificity and standardization in repeated studies that proved by testing in patients with atopic diseases in mycological clinic MAPO and medicinal institution of St. -Peterburgh and Russia. Allergens from mycelial fungi are used for immune diagnosis of mycogenic sensitization and allergy. EFFECT: improved culturing method, valuable medicinal properties of allergen. 2 dwg, 1 tbl, 1 ex
1,242,882. Anti-inflammatory compositions. BYK-GULDEN LOMBERG CHEMISCHE FABRIK G.m.b.H. 17 Oct., 1968 [18 Oct., 1967], No. 49229/68. Heading A5B. Pharmaceutical compositions, having antiinflammatory activity and particularly useful for the treatment of rheumatic diseases, comprise a pharmaceutically acceptable carrier and a salt of a substituted malonic acid hydrazide that has been obtained by the process claimed in Specification 1,164,039, the salt having the general formula wherein R is a straight chain, branched or cyclic alkyl or alkenyl radical having up to 10 carbon atoms and optionally interrupted by an oxygen, sulphur or imino group, an aryl or aralkyl wherein the aromatic ring is optionally substituted by halogen, hydroxy, alkoxy, nitro, amino, or dialkylamino, R 1  is hydrogen or any of the radicals defined for R, Ar is phenyl which is optionally substituted by halogen, alkyl and/or alkoxy groups of up to 3  carbon atoms inclusive or hydroxy and X is a metal other than sodium, n being the valency of the metal, or X is the ammonium radical or a quarternary ammonium radical in which at least one of the hydrogen atoms of the ammonium radical is replaced by optionally substituted alkyl or aralkyl. The compositions may be in the form of a dragee, tablet, syrup, ointment, suppository or injection solution and may include&#39; another pharmacodynamically active substance such as fever-reducing substances, anti-allergic substances and inflammation-inhibiting agents such as prednisolone.
PURPOSE: To provide the subject new compound consisting of a tripeptide containing a specific acidic amino acid, having strong inhibiting action on endothelin and vasodilating action and useful as an endothelin antagonistic agent, a vasodilator, etc., for the treatment of myocardial infarction, stenocardia, etc. CONSTITUTION: This new tripeptide (its salt or hydrate) is expressed by formula (R&lt;1&gt; is an alkyl, an aryl, an aryl-lower alkyl, an alkoxy, an aryloxy, etc.; R&lt;2&gt; is H, an alkyl, an aryl, an aryl-lower alkyl, formyl, a lower acyl, etc.; one of R&lt;3&gt; and R&lt;4&gt; is hydroxyl and the other is an alkoxy or an alkylamino; A is methylene or ethylene). It has endothelin antagonistic action and vasodilating action and useful e.g. as an agent for the treatment of heart diseases, respiratory tract diseases, cardiovascular diseases, renal diseases, hepatic diseases, bone diseases, vascular disorders, etc. The compound can be produced either by condensing amino acids one by one or condensing condensation products each composed of plural amino acids and optionally removing the protective groups by alkali hydrolysis, catalytic hydrogenative decomposition, etc.
1426450 Treating hair L&#39;OREAL 3 April 1973 [4 April 1972] 15845/73 Heading D1P A two-compartment pack for use in the oxidation stage of a permanent waving procedure for hair, contains components which on admixture produce a rise in temperature. The first compartment contains a first component comprising at least one sulphite, metabisulphite, bisulphite or thiourea, and the second compartment contains a second component comprising hydrogen peroxide, the contents of the two compartments being such that after mixing the entire contents of the two compartments the rise in temperature is 15-25‹C and the concentration of hydrogen peroxide in the resulting composition (at the end of the oxidation-reduction reaction) is between 0.5 and 3%, preferably between 0.75 and 1.5% by weight. The self-heating compositions resulting from admixture of the first and second components may be applied in a process for permanently waving hair, by treating the hair, after it has been reduced and rinsed while constrained in a deformed state, with the self-heating composition for a period of 1-15 minutes, followed by removing the constraining means and rinsing the hair. The first component may be in solid form. The second component may contain, in addition to hydrogen peroxide, a thickener e.g .carboxymethyl cellulose, hydroxymethyl cellulose or a wax. Citric acid, phenacetin, hydroxyquinoline sulphate, perfume and dyestuff may also be present.
&lt;P&gt;PROBLEM TO BE SOLVED: To easily display another medical image relating to the medical image displayed by simple operation.  &lt;P&gt;SOLUTION: In a medical image display 40, inspecting information and the series information corresponding to inspecting information are acquired from a display frame managing table in the display image in a selecting condition in an image reading screen when a series button is operated to be pushed down by a doctor via an operation section 42. Then, display items showing the content of each series image shown in one view are generated based on the acquired series information. A pull down menu comprising the above display items is developed and shown in a lower section of the series button. The pull down menu is shown only during the doctor operates to push down the series button and automatically not gets shown as canceling the pushing down operation.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To provide a biomarker useful to grasp a cancer patient&#39;s prognosis and its application.SOLUTION: A biomarker for cancer patient&#39;s prognosis estimation is made of RFP. The biomarker for prognosis estimation may be for colon cancer or endometrium cancer. A reagent for cancer patient&#39;s prognosis estimation is made of an anti-RFP antibody. The reagent for prognosis estimation may be for colon cancer or endometrium cancer. A cancer patient&#39;s kit for prognosis estimation may includes the reagent. The kit for prognosis estimation may be for colon cancer or endometrium cancer.
PROBLEM TO BE SOLVED: To obtain a liquid cleanser composition giving a fresh touch on rinsing, low in irritation to skin, not giving a dry touch after dried, giving a wet touch, and especially useful for washing skins by dissolving a specific phosphoric ester and a water-soluble aluminum salt in a liquid medium. SOLUTION: (A) An anionic surfactant comprising a phosphoric ester of the formula (R&lt;1&gt; is a 8-15C hydrocarbon group; X&lt;1&gt; , X&lt;2&gt; are each independently H, an alkali metal, ammonium, a basic amino acid, etc.) and (B) a water-soluble aluminum salt (alum, etc.) are homogeneously dissolved in (C) a liquid medium with stirring. The components A and B are compounded in amounts of 5-50wt.% and 0.015wt.%, respectively, based on the whole amount of the composition. When the liquid medium is water, the water is preferably compounded in an amount of 40-90wt.% based on the whole amount of the composition.
An antivirus agent is obtained by maintaining a solution of oxytetracycline under mildly alkaline conditions until substantial antivirus activity (test micro-organism influenza virus) is imparted to the solution.  The solvent may be water, a water-miscible organic solvent, e.g. alcohol or a mixture thereof.  A pH of 10 to 12 and a temperature of 20 DEG  to 100 DEG  C. is preferred.  The higher the temperature, the shorter the digestion time.  Thus at 20 DEG  to 35 DEG  C. the time is 2 to 10 days; at 90 DEG  to 100 DEG  C. the time is 1/2 to 3 hours.  The lower temperature produces the most active product.  The agent may be isolated from the solution by (a) freezy-drying or (b) acidifying to pH 2 to 4 and filtering off the separated solid.  The original solution may be rendered alkaline by an organic or inorganic base, the alkali metal hydroxides being preferred.  Any strong acid may be used in step (b); preferred are phosphoric, sulphuric or hydrochloric. The antivirus agent is active against the influenza A virus; has low solubility in dilute, aqueous acid; the acid form is soluble in acetone, methanol, butanol and pyridine, but insoluble in ether, chloroform, dioxane and acetonitrile; its activity against Klebsiella pneumoniae is preferably less than 10 per cent of that of oxytetracycline.  The agent may be used therapeutically with other antibiotics (see Group VI).ALSO:A therapeutic preparation comprises a solution of an antivirus agent obtained by maintaining oxytetracycline under mildly alkaline conditions until substantial activity against the influenza A virus is obtained (see Group IV (b)].  Optional additions are penicillin, streptomycin, &#34;Viomycin&#34; (R.T.M.) or oxytetracyline.
A method for determining the pathogenicity/benignity of a genomic variant in connection with a given disease is described. Such a method comprises the steps of accessing genomic data (D) comprising a list of the patient&#39;s genomic variants and then, for each variant detected, verifying (S1), by electronic computing means, whether or not the variant meets each of a plurality of predefined pathogenicity/benignity criteria. Each of such pathogenicity/benignity criterion is a proposition, which can be true or false, related to the variant, in connection with a first type or a second type condition, and wherein at least one of the aforesaid criteria refers to a first type condition, and at least another one of the criteria refers to a second type condition. A &#34;first type condition&#34; comprises a statistical condition and/or a previously known condition. A &#34;second type condition&#34; comprises a patient-specific condition. Each pathogenicity/benignity criterion is associated with a level of evidence, indicative of a condition or level of pathogenicity or benignity. The method then provides preparing (S2) input information (I) for a trained algorithm (A), trained using artificial intelligence and/or machine learning techniques. The input information (I) comprises, for each variant and for each level of evidence, information relative to the number of pathogenicity/benignity criteria associated with the level of evidence which are met by the variant. Finally, the method comprises processing the aforementioned input information by the trained algorithm (A), to obtain an output information (O) representative of the pathogenicity/benignity of each of the considered genomic variants. The algorithm (A) is trained in a preliminary step of training (S0), based on a training dataset of known cases, providing in input the input information (I0) calculated for the known cases, and training the algorithm based on the knowledge of the pathogenicity/benignity of the respective known cases.